Adam S. Sperling

Learn More
Multiple myeloma is an incurable plasma cell malignancy with a complex and incompletely understood molecular pathogenesis. Here we use whole-exome sequencing, copy-number profiling and cytogenetics to analyse 84 myeloma samples. Most cases have a complex subclonal structure and show clusters of subclonal variants, including subclonal driver mutations.(More)
Myelodysplastic syndrome (MDS) is a clonal disease that arises from the expansion of mutated haematopoietic stem cells. In a spectrum of myeloid disorders ranging from clonal haematopoiesis of indeterminate potential (CHIP) to secondary acute myeloid leukaemia (sAML), MDS is distinguished by the presence of peripheral blood cytopenias, dysplastic(More)
Recent work has delineated mutational profiles in multiple myeloma and reported a median of 52 mutations per patient, as well as a set of commonly mutated genes across multiple patients. In this study, we have used deep sequencing of RNA from a subset of these patients to evaluate the proportion of expressed mutations. We find that the majority of(More)
Genomic lesions are not investigated during routine diagnostic workup for multiple myeloma (MM). Cytogenetic studies are performed to assess prognosis but with limited impact on therapeutic decisions. Recently, several recurrently mutated genes have been described, but their clinical value remains to be defined. Therefore, clinical-grade strategies to(More)
Patients with relapsed AML have a poor prognosis and limited responses to standard chemotherapy. Lenalidomide is an immunomodulatory drug that may modulate anti-tumor immunity. We performed a study to evaluate the safety and tolerability of lenalidomide with mitoxantrone, etoposide and cytarabine (MEC) in relapsed/refractory AML. Adult patients with(More)
The presence of hematologic malignancy–associated mutations in the blood of individuals without cytopenias or dysplasia has been termed clonal hematopoiesis of indeterminate potential (CHIP), a clinical entity associated with increased age, risk of developing hematologic malignancy, and decreased overall survival. Two papers in this issue of Blood take(More)
Scientific computing workloads are well suited to parallel accelerators such as GPGPUs and the Intel Xeon Phi. While these accelerators can provide greater performance than traditional CPUs due to their parallel architectures and greater memory bandwidth, their maximum workload size is limited by relatively small memory capacity. To solve this problem, data(More)
  • 1